Details

Autor(en) / Beteiligte

• Mosquera Orgueira, Adrián
• Bao Pérez, Laura
• Mosquera Torre, Alicia
• Peleteiro Raíndo, Andrés
• Cid López, Miguel
• Díaz Arias, José Á
• Ferreiro Ferro, Roi
• Antelo Rodríguez, Beatriz
• González Pérez, Marta S
• Albors Ferreiro, Manuel
• Alonso Vence, Natalia
• Pérez Encinas, Manuel M
• Bello López, José L
• Martinelli, Giovanni
• Cerchione, Claudio

Titel

FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives

Ist Teil von

• Minerva medica, 2020-10, Vol.111 (5), p.427

Ort / Verlag

Italy

Erscheinungsjahr

2020

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Mutations in the FMS-like tyrosine kinase 3 (FLT3) gene arise in 25-30% of all acute myeloid leukemia (AML) patients. These mutations lead to constitutive activation of the protein product and are divided in two broad types: internal tandem duplication (ITD) of the juxtamembrane domain (25% of cases) and point mutations in the tyrosine kinase domain (TKD). Patients with FLT3 ITD mutations have a high relapse risk and inferior cure rates, whereas the role of FLT3 TKD mutations still remains to be clarified. Additionally, growing research indicates that FLT3 status evolves through a disease continuum (clonal evolution), where AML cases can acquire FLT3 mutations at relapse - not present in the moment of diagnosis. Several FLT3 inhibitors have been tested in patients with FLT3-mutated AML. These drugs exhibit different kinase inhibitory profiles, pharmacokinetics and adverse events. First-generation multi-kinase inhibitors (sorafenib, midostaurin, lestaurtinib) are characterized by a broad-spectrum of drug targets, whereas second-generation inhibitors (quizartinib, crenolanib, gilteritinib) show more potent and specific FLT3 inhibition, and are thereby accompanied by less toxic effects. Notwithstanding, all FLT3 inhibitors face primary and acquired mechanisms of resistance, and therefore the combinations with other drugs (standard chemotherapy, hypomethylating agents, checkpoint inhibitors) and its application in different clinical settings (upfront therapy, maintenance, relapsed or refractory disease) are under study in a myriad of clinical trials. This review focuses on the role of FLT3 mutations in AML, pharmacological features of FLT3 inhibitors, known mechanisms of drug resistance and accumulated evidence for the use of FLT3 inhibitors in different clinical settings.